PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.76%
Positive EBIT growth while TRVN is negative. John Neff might see a substantial edge in operational management.
10.76%
Positive operating income growth while TRVN is negative. John Neff might view this as a competitive edge in operations.
11.35%
Net income growth 1.25-1.5x TRVN's 9.25%. Bruce Berkowitz would see if strategic cost cutting or product mix explains this difference.
31.03%
EPS growth above 1.5x TRVN's 12.41%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
31.72%
Diluted EPS growth above 1.5x TRVN's 12.41%. David Dodd would see if there's a robust moat protecting these shareholder gains.
29.31%
Share count expansion well above TRVN's 3.96%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
29.44%
Diluted share count expanding well above TRVN's 3.96%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
2.31%
OCF growth under 50% of TRVN's 60.72%. Michael Burry might suspect questionable revenue recognition or rising costs.
3.06%
FCF growth under 50% of TRVN's 60.72%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-254578.19%
Negative 10Y OCF/share CAGR while TRVN stands at 89.52%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
64.50%
5Y OCF/share CAGR at 50-75% of TRVN's 91.06%. Martin Whitman would question if the firm lags in monetizing revenue effectively.
73.57%
3Y OCF/share CAGR at 75-90% of TRVN's 90.83%. Bill Ackman would press for improvements in margin or overhead to catch up.
-9976.84%
Negative 10Y net income/share CAGR while TRVN is at 85.08%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-124.34%
Negative 5Y net income/share CAGR while TRVN is 88.37%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
76.73%
3Y net income/share CAGR 75-90% of TRVN's 86.22%. Bill Ackman might push for an operational plan to match or beat the competitor’s short-term growth.
1493.31%
Positive growth while TRVN is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
-38.28%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-74.77%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
78.33%
Positive asset growth while TRVN is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
127.26%
Positive BV/share change while TRVN is negative. John Neff sees a clear edge over a competitor losing equity.
-9.95%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-7.53%
Our R&D shrinks while TRVN invests at 26.37%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-21.01%
We cut SG&A while TRVN invests at 8.20%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.